Cipla, Rocket India announce Rs 300 crore expansion plans in Karnataka; Blackstone eyes data centres

Cipla and Rocket India will invest Rs 300 crore in Karnataka's manufacturing facilities. Blackstone is exploring investments in data centers and renewable energy infrastructure. Saint-Gobain plans to expand its manufacturing footprint within the state. Horizon is encouraged to consider industrial projects in tier two cities. These announcements occurred during Karnataka's investment roadshow in Mumbai.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/W46dIZb
via IFTTT

Read More

IPA seeks to regularise 'legacy' drugs

The Indian Pharmaceutical Alliance seeks to regularize many drugs. These drugs have been marketed for years without central approval. Examples include sodium valproate and carbamazepine tablets. Regulatory gaps have persisted for over a decade. This situation requires urgent attention from drug authorities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vClqPwm
via IFTTT

Read More

Dr Reddy's Laboratories launches generic Sugammadex injection in the United States

Dr Reddy's Laboratories has launched its generic Sugammadex injection in the United States. This new product reverses muscle relaxant effects given during surgical procedures. The company's hospital portfolio expands with this important medicine's availability. Sugammadex injection is a vertically integrated product manufactured through Dr Reddy's global network. This launch occurred on the first day of generic availability in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SiFyJOU
via IFTTT

Read More

India pharma sector to miss 2030 sales target amid tariff and shipping woes, trade body says

India's pharmaceutical industry is expected to reach$80-90 billion by 2030, well below its earlier$130 billion target, as U.S. tariff uncertainty and Middle East shipping disruptions hurt exports, Pharmaceuticals Export Promotion Council of India Chairman Namit Joshi told Reuters.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/867Jmlf
via IFTTT

Read More

Private equity firm Creador in talks to buy into generic drug co Leeford Health

Private equity firm Creador is in advanced talks to acquire a stake. The firm expects to invest ₹800 crore in Leeford Healthcare. This acquisition would value the generic drugmaker at ₹8,000-₹8,500 crore. Leeford Healthcare is a diversified pharmaceutical and wellness company. This deal marks the company's first ownership dilution to an external investor.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Kf5xhTv
via IFTTT

Read More

Two-wheeled road ambulance to run from October 1, 2027

The Centre has proposed introducing a regulatory framework for two-wheeled road ambulances, which will become operational from October 1, 2027, to improve emergency medical access in rural, remote and hilly areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kKeP0ZV
via IFTTT

Read More

Losing weight fast on GLP-1 drugs? Your hair could be the next thing to go

Dermatologists report increased hair loss among GLP-1 drug users experiencing rapid weight reduction. This side effect, often telogen effluvium, stems from nutritional deficiencies and metabolic stress. Many patients start these medications without proper medical supervision, influenced by social media trends. Studies show a high prevalence of hair shedding, particularly among women and significant weight losers. Doctors advise medical supervision and balanced nutrition to manage this temporary condition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iSpeEKr
via IFTTT

Read More